SEC Form 8-K Summary
Registrant: Nukkleus Inc. The request identifies T3 Defense Inc., but the filing names Nukkleus Inc. as the registrant.
Reporting date: May 6, 2024; filed May 8, 2024. The filing reports a Nasdaq continued-listing deficiency under Item 3.01.
Business Context and Reporting Period
Nukkleus Inc., a Delaware corporation headquartered in Jersey City, New Jersey, reported that Nasdaq notified the company that its common stock had traded below the minimum bid-price requirement for continued listing.
Key Financial and Listing Metrics
- Minimum bid-price requirement: At least $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
- Observed deficiency: The closing bid price was below $1.00 for 35 consecutive business days.
- Financial metrics: The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-financial data.
- Immediate trading status: The notice had no immediate effect on the listing or trading of the common stock on Nasdaq Capital Market.
Material Changes and Compliance Timeline
- Nasdaq granted the company 180 calendar days, through November 4, 2024, to regain compliance.
- Compliance may be restored if the stock closes at or above $1.00 for at least 10 consecutive business days during the compliance period.
- If the company does not regain compliance during the initial period, it may qualify for an additional 180-day period, subject to meeting Nasdaq’s market-value and other initial-listing requirements and providing written notice of its intent to cure the deficiency.
Outlook, Risks, and Contingencies
Management stated that it intends to monitor the stock’s minimum bid price and may consider available options to regain compliance. The filing provides no specific remediation plan, reverse-split proposal, financing plan, or other corporate action.
If the company is not eligible for additional time or Nasdaq determines that the deficiency is unlikely to be cured, Nasdaq may issue a delisting notice. The company could appeal a delisting determination, but the filing states that there is no assurance the appeal would be successful. The company also cautioned that there is no assurance it will regain compliance or satisfy other Nasdaq listing criteria.
Important Facts for Investors to Verify
- Whether the company’s closing bid price reaches at least $1.00 for the required period before November 4, 2024.
- Whether Nasdaq grants an additional compliance period and whether the company satisfies all related eligibility requirements.
- Any subsequent corporate actions intended to address the deficiency, including a potential reverse stock split or other capital-markets transaction.
- Any later Nasdaq delisting notice, appeal, or change in the company’s listing status.
- The correct issuer identity, because the supplied request references T3 Defense Inc. while the filing is for Nukkleus Inc.